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The yeast exosome is a complex of 3* 3 5* exoribo-
nucleases. Sequence analysis identified putative human
homologues for exosome components, although several
were found only as expressed sequence tags. Here we
report the cloning of full-length cDNAs, which encode
putative human homologues of the Rrp40p, Rrp41p, and
Rrp46p components of the exosome. Recombinant pro-
teins were expressed and used to raise rabbit antisera.
In Western blotting experiments, these decorated HeLa
cell proteins of the predicted sizes. All three human
proteins were enriched in the HeLa cells nucleus and
nucleolus, but were also clearly detected in the cyto-
plasm. Size exclusion chromatography revealed that
hRrp40p, hRrp41p, and hRrp46p were present in a large
complex. This cofractionated with the human homo-
logues of other exosome components, hRrp4p and PM/
Scl-100. Anti-PM/Scl-positive patient sera coimmunopre-
cipitated hRrp40p, hRrp41p, and hRrp46p demon-
strating their physical association. The immunoprecipi-
tated complex exhibited 3*3 5* exoribonuclease activity
in vitro. hRrp41p was expressed in yeast and shown to
suppress the lethality of genetic depletion of yeast
Rrp41p. We conclude that hRrp40p, hRrp41p, and
hRrp46p represent novel components of the human exo-
some complex.
In both bacteria and eukaryotes, the processing and degra-
dation of many RNA species involves multiprotein complexes
(reviewed in Refs. 1–4). The Escherichia coli degradosome in-
cludes the endoribonuclease E (RNase E), the 39 3 59 exonu-
clease polynucleotide phosphorylase, the DEAD box RNA heli-
case RhlB, and several additional proteins whose role is
unclear (5–7). Related complexes are implicated in RNA proc-
essing in chloroplasts and mitochondria (8–10). The yeast exo-
some contains at least 11 components, which are known or
predicted to be 39 3 59 exoribonucleases (11, 12). Ten of these
(Rrp4p, Rrp40–46p, Mtr3p, and Csl4p) have been demon-
strated to be encoded by essential genes. These 10 components
were found in both cytoplasmic and nuclear complexes,
whereas the nonessential RRP6 gene product was detected
only in the nucleus (11, 13).
The 39 processing of many RNAs is affected by the absence or
mutation of exosome components. The nuclear exosome is im-
plicated in the processing of ribosomal RNA (rRNA), spliceoso-
mal small nuclear RNAs, and small nucleolar RNAs, as well as
the degradation of pre-rRNA spacers and unspliced
pre-mRNAs (12–22). The cytoplasmic exosome complex is in-
volved in the 39 3 59 pathway of mRNA degradation (22). The
activity of the exosome complex may be regulated by cofactors
including, for example, the putative ATP-dependent DEVH box
RNA helicases Dob1p and Ski2p (23, 24).
Human cells also contain a multiprotein complex that is
related to the yeast exosome (11). This complex, initially des-
ignated as the polymyositis/scleroderma (PM/Scl)1 overlap syn-
drome particle and herein referred to as the human exosome,
was reported to contain 11 (25) to 16 (26) subunits ranging from
20 to 110 kDa. Two proteins of this complex were identified as
autoantigens, which are targeted by autoantibodies present in
the serum of patients suffering from myositis, scleroderma, or
PM/Scl overlap syndrome (27). All tested anti-PM/Scl-positive
sera recognize a nuclear protein, known as PM/Scl-100, while
some also recognize a protein migrating at about 75 kDa (PM/
Scl-75) in SDS-polyacrylamide gel electrophoresis (28–30). PM/
Scl-100 and -75 are the human homologues of yeast Rrp6p and
Rrp45p, respectively (13, 31). The cloning of five additional
human homologues of yeast exosome components has been
reported, while ESTs were identified for three further homo-
logues (11, 12, 32–34). However, detailed characterization of
human exosome components is limited. The functional conser-
vation has been reported for hRrp4p, hRrp44p/hDis3p, and
hCsl4p, and direct evidence for complex formation has been
described for hRrp4p and the PM/Scl autoantigens (11).
Here we report the cloning of the human homologues of yeast
Rrp40p, Rrp41p (also designated Ski6p), and Rrp46p. Subcel-
lular distribution, coimmunoprecipitation, and in vivo as well
as in vitro activity assays show that these three proteins are
components of the human exosome.
EXPERIMENTAL PROCEDURES
Isolation of hRrp40p, hRrp41p, and hRrp46p cDNAs—Data base
homology searches revealed human ESTs, which could be assembled
into contigs with apparent homology to yeast exosome components (11).
ESTs homologous to yeast Rrp40p (accession numbers AA747303,
AA282142, H25417, and AA057832), Rrp41p/Ski6p (accession numbers
U46288 and AA129848) and Rrp46p (accession numbers AA428915,
* This work was supported in part by the Netherlands Foundation for
Chemical Research with financial aid from the Netherlands Organiza-
tion for Scientific Research, the Netherlands Technology Foundation,
and the Wellcome Trust. The costs of publication of this article were
defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted
to the GenBankTM/EBI Data Bank with accession number(s)
AF281132–AF281134.
¶ To whom correspondence should be addressed. Tel.: 31-24-3616847;
Fax: 31-24-3540525; E-mail: g.pruijn@bioch.kun.nl.
1 The abbreviations used are: PM/Scl, polymyositis/scleroderma;
PBS, phosphate-buffered saline; PCR, polymerase chain reaction; VSV,
vesicular stomatitis virus G epitope; EST, expressed sequence tag; GST,
glutathione S-transferase; ORF, open reading frame; RACE, rapid am-
plification of cDNA ends; contig, group of overlapping clones.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 276, No. 9, Issue of March 2, pp. 6177–6184, 2001
© 2001 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 6177
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on O
ctober 8, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
AA461395, and AA426493) were selected. Nucleotide sequences of five
independent clones of each EST were determined by the dideoxynucle-
otide termination method. Complete (hRRP41) or partial (hRRP40 and
hRRP46) open reading frames (ORFs) were identified. To isolate addi-
tional cDNAs corresponding to sequences required to complete the
ORFs, human teratocarcinoma and placenta cDNA libraries were
screened by PCR using gene-specific primers for hRRP40 and hRRP46
(hRrp40-a or hRrp46-a, respectively; see Table I) in combination with
lLacZ library primers. The largest PCR products were identified by
Southern blotting and cloned into the pCRII-TOPO vector (Invitrogen).
Sequence analysis revealed putative start codons for both hRRP40 and
hRRP46. The cDNAs isolated from the teratocarcinoma cDNA library
were ligated to the coding sequence present in the EST clones. To
further investigate the 59 ends of the corresponding mRNAs, a 59 RACE
analysis was performed using total human placenta RNA (Smart RACE
cDNA amplification kit, CLONTECH). Gene specific primers used for
the 59 RACE analysis were hRrp40-b, hRrp40-c, hRrp41-b, hRrp41-c,
hRrp46-b, and hRrp46-c. Finally, primers (25S and 23AS) were de-
signed to introduce restriction sites at the termini of the isolated cDNAs
to allow cloning into appropriate expression vectors (see below). The
sequences of the oligonucleotides used in the cloning of hRRP40,
hRRP41, and hRRP46 are listed in Table I.
Complementation Experiments—To test for complementation of the
yeast conditional alleles GAL::rrp40, GAL::rrp41, and GAL::rrp46,
strains P147, P118, and YCA21 were transformed with plasmids
phRRP40, phRRP41, and phRRP46, respectively (Table II). Comple-
mentation of the conditional alleles was assayed by growth on repres-
sive YPD medium at 30 °C and compared with the growth of the
isogenic wild-type strain (YDL401). Plasmids were constructed by in-
serting the cDNA of hRRP40, hRRP41, and hRRP46 into plasmid
pNOPPATA1L (CEN, LEU2) (generously provided by E. Hurt) under
the control of a NOP1 promotor, at restriction sites NdeI-BamHI for
hRRP40 and hRRP41, and NdeI-SalI for hRRP46.
Expression of Recombinant Proteins—For prokaryotic expression,
the hRRP40, hRRP41, and hRRP46 cDNAs were cloned into pET16b
and/or pGEX2T’G resulting in N-terminally His-tagged or glutathione
S-transferase (GST)-tagged recombinant proteins, respectively. His-
tagged proteins were purified by Ni21-NTA-agarose beads (Qiagen)
essentially according to the manufacturer’s protocol. GST-tagged pro-
teins were purified as described previously (35). In addition, recombi-
nant N-terminally His-tagged hRrp40p and hRrp46p were expressed in
and purified from SF-9 cells using the Bac-to-Bac baculovirus expres-
sion system according to the manufacturer’s protocol (Life Technolo-
gies, Inc.).
Generation of Rabbit Antisera—Polyclonal antisera were raised in
rabbits by immunization with 100–200 mg of purified recombinant
protein according to standard procedures (36). Serum H70 (anti-
hRrp40p), H71 (anti-hRrp41p), and H73 (anti-hRrp46p) were generated
using His-tagged hRrp40p expressed in E. coli, His-, and GST-tagged
hRrp41p expressed in E. coli and His-tagged hRrp46p expressed in the
baculovirus system, respectively.
Western Blot Analysis—For Western blot analysis, autoimmune pa-
tient and rabbit antisera were diluted 5000- and 500-fold, respectively,
in blocking buffer (3% nonfat milk, phosphate-buffered saline (PBS),
0.1% Tween 20). As secondary antibody, horseradish peroxidase-conju-
gated rabbit anti-human IgG or swine anti-rabbit IgG (Dako Immuno-
globulins) were used at a 2500-fold dilution in blocking buffer. Visual-
ization was performed by chemiluminescence.
Transient Transfection of HEp-2 Cells and Indirect Immunofluores-
cence—For transfection, hRRP40, hRRP41, and hRRP46 cDNAs were
cloned into the pCI-Neo vector (Promega), which contained a sequence
element encoding the vesicular stomatitis virus G epitope (VSV) to
allow expression of either N-terminally or C-terminally VSV-tagged
proteins. HEp-2 cells were grown to 80% confluence by standard tissue
culture techniques in Dulbecco’s modified Eagle’s medium (Life Tech-
nologies, Inc.) containing 10% fetal calf serum. Approximately 2 3 106
cells were transfected with 10–20 mg of DNA in 800 ml of Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum by
electroporation, which was performed at 270 V and 950 microfarads
using a Gene Pulser II (Bio-Rad). After transfection, cells were seeded
onto coverslips and cultured for 24 h. Cells were washed twice with
PBS, fixed with methanol for 5 min at 220 °C, briefly rinsed in acetone,
air-dried, and stored at 220 °C until use.
For indirect immunofluorescence, fixed cells were subsequently in-
cubated for 1 h at room temperature with an affinity-purified mouse
anti-VSV tag monoclonal antibody (Roche Molecular Biochemicals) and
subsequently with fluorescein isothiocyanate-conjugated rabbit anti-
mouse Ig (Dako Immunoglobulins) and fluorescein isothiocyanate-con-
jugated swine anti-rabbit Ig (Dako Immunoglobulins). All antibodies
were diluted 50-fold in PBS. Cells were mounted with PBS/glycerol
containing Mowiol, and bound antibodies were visualized by fluores-
cence microscopy.
Preparation of HeLa Cell Extracts—Cytoplasmic and nuclear HeLa
cell extracts were prepared according to a modification of the Dignam
procedure essentially as described by Wahle et al. (37).
Immunoprecipitation—Immunoprecipitations were essentially per-
formed as described previously (38). Per immunoprecipitation, 10 ml of
patient serum or 20 ml of rabbit serum was coupled to 10 ml of protein
A-agarose (Biozym) and extract of 2.5 3 106 HeLa cells was used. For
Western blotting, the immunoprecipitates were heated for 5 min in SDS
sample buffer and fractionated by SDS-polyacrylamide gel electro-
phoresis (39).
Size Exclusion Chromatography—Nuclear and cytoplasmic extract of
75 3 106 HeLa cells was fractionated by automated liquid chromatog-
raphy (BioLogic, Bio-Rad) using the Superdex 200 HR 10/30 column
(Amersham Pharmacia Biotech) in a buffer containing 10 mM Hepes-
KOH, pH7.9, and 100 mM KCl at 0.5 ml/min. Thirty samples of ;330 ml
were collected, and proteins were immediately precipitated by the ad-
dition of four volumes of acetone. After overnight incubation at 270 °C,
pellets were collected by centrifugation at 13,000 3 g for 30 min.
Air-dried pellets were solubilized in SDS sample buffer, and proteins
were analyzed by Western blotting (20% of each fraction). To estimate
complex sizes, gel filtration standards (Bio-Rad), including thyroglobin
(670 kDa), bovine IgG (158 kDa), chicken ovalbumin (44 kDa), equine
myoglobin (17 kDa), and vitamin B12 (1.35 kDa), were analyzed as
described above.
In Vitro Exonuclease Assay—Immunoprecipitations were performed
as described above. After removal of nonbinding material, immune
complexes bound to the protein A-agarose beads were washed twice
with buffer A (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5 mM MgCl2, 1 mM
Na2HPO4). Substrate solution (
32P-labeled substrate in buffer A) was
added to the protein A beads, and the suspension was incubated at
37 °C with gentle agitation. Formamide loading buffer was added to
samples taken at regular intervals and immediately frozen until anal-
ysis. Samples were analyzed by denaturing polyacrylamide gel electro-
phoresis followed by autoradiography. Substrates, transcribed in vitro
TABLE I
Sequences of gene-specific oligonucleotides used in the cloning of hRrp40p, hRrp41p, and hRrp46p
Underlined sequences encode introduced restriction sites to enable cloning into the appropriate expression vectors. Start and stop codons are
indicated in bold.
hRrp40-a 59-CAACCACAAACTGGCCATAGATG-39
hRrp40-b 59-GTCCACCCAGTAAACACCGCCGCCG-39
hRrp40-c 59-CTGCCACTGCCGGGCTCCTTGTGAC-39
hRrp40–5S 59-CAGAATTCACATATGGCCGAACCTGCGTCTGTC-39
hRrp40–3AS 59-CTGGATCCGTCGACTCATCTAGAGGTACCACTTTCTGCCAATCTGGAGAAG-39
hRrp41-b 59-ATATTGACAGTTCACTAGGGCC-39
hRrp41-c 59-CTCGTGCGGGCCGTAGACCACAGCC-39
hRrp41–5S 59-CTGAATTCACATATGGCGGGGCTGGAGCTCTTG-39
hRrp41–3AS 59-GTGGATCCGTCGACTCATCTAGAGGTACCGTCCCCCAGCAAGATAGAGGC-39
hRrp46-a 59-CAATCTTCGGCCTCAGGATCAC-39
hRrp46-b 59-GCGCAGGCGACCCCACAGAAGAGAG-39
hRrp46-c 59-CCGCATGGGCACACCTGCATCCACC-39
hRrp46–5S 59-CTGAATTCACATATGGAGGAGGAGACGCATACT-39
hRrp46–3AS 59-CTGAATTCGTCGACTCATCTAGAGGTACCCAGAGCTGCAGGCTCAAGGAG-39
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by T3 RNA polymerase from XbaI-linearized pBS(2) template (Strat-
agene), were labeled randomly using [32P]UTP (Amersham Pharmacia
Biotech) or at the 39 end using [32P]pCp (Amersham Pharmacia Bio-
tech), respectively (38).
RESULTS
Cloning of Human Homologues of Yeast Rrp40p, Rrp41p/
Ski6p, and Rrp46p—Full length cDNAs encoding human ho-
mologues of the S. cerevisiae Rrp40p, Rrp41p/Ski6p, and
Rrp46p (open reading frames YOL142w, YGR195w, and
YGR095c, respectively) were generated based upon EST clones,
cDNA-specific PCR fragments isolated from a teratocarcinoma
cDNA library, and 59 RACE products obtained from human
placental RNA (Fig. 1). These sequence data have been sub-
mitted to the DDBJ/EMBL/GenBanky data bases under acces-
sion numbers AF281132, AF281133, and AF281134. From the
cDNAs, hRrp40p, hRrp41p, and hRrp46p have predicted mo-
lecular masses of 31 kDa (275 amino acids), 27 kDa (245 amino
acids), and 26 kDa (235 amino acids), respectively. The data in
Table III show that the predicted protein sequences of
hRrp40p, hRrp41p, and hRrp46p are relatively well conserved
to the S. cerevisiae (Sc) homologues, and clear homologues are
also present in M. musculus (Mm), C. elegans (Ce), and S.
pombe (Sp). hRrp41p and hRrp46p are both homologous to E.
coli RNase PH (11, 12, 31) and therefore show homology to each
other, whereas hRrp40p is not significantly homologous to
hRrp41p or hRrp46p.
Two genomic sequences for hRRP46 are present in the data
base; a complete sequence on chromosome 19 and a partial
sequence (accession no. L08634) corresponding to nucleotides
223 to 1150 of the isolated hRRP46 cDNA clone. A T/C poly-
morphism is evident in these sequences, resulting in an amino
acid substitution (methionine/threonine) at position 5 of
hRrp46p. Both types of cDNA were obtained from the 59 RACE
analyses, and ESTs exist with each nucleotide. In the studies
described below, the cDNA clone encoding threonine at position
5 was used. Polymorphism was also evident in the region 59 to
the ORF, with an in frame upstream stop codon present in
L08634, but not in the chromosome 19 sequence. In the latter,
the ORF could potentially extend 33 amino acids further 59.
However, no cDNA that extends beyond 23 nucleotides of the
59-untranslated region was isolated and the extended ORF
sequence would be in poorer agreement with the molecular
weight predicted from the observed gel migration of the protein
from HeLa cell lysates, compared with that synthesized in E.
coli. Therefore, we believe that the cDNA used encodes the
full-length protein. An EST with an internal truncation in the
hRrp46p ORF was also found, presumably as a consequence of
alternative splicing, that leads to a frameshift at Gly-85 and
truncation of the polypeptide.
Two EST clones encoding a possible splicing variant of
hRrp40p (accession nos. AA282142 and H25417) were identi-
fied, and the same sequence is listed as apoptosis-related pro-
tein PNAS-3 mRNA (accession no. AF229833). These lack an
internal region of the ORF leading to frameshift at Gln-158 and
truncation of the polypeptide.
hRrp41p Encodes a Functional Homologue of Yeast Rrp41p/
Ski6p—To test whether hRrp40p, hRrp41p, or hRrp46p can
complement mutations in the corresponding yeast genes, the
full-length cDNAs were cloned into yeast expression vectors
under the control of the strong constitutive NOP1 promoter
(see “Experimental Procedures”). The constructs were trans-
formed into yeast strains in which the endogenous genes were
subject to GAL regulation; strains GAL::rrp40, GAL::rrp41,
and GAL::rrp46. Western blotting (data not shown) confirmed
that each of the human proteins was well expressed. In plate
assays, the growth inhibition of the GAL::rrp41 strain on glu-
cose medium was efficiently suppressed by expression of
hRrp41p (Fig. 2), showing it to be the functional homologue of
Rrp41p/Ski6p. The expression of hRrp40p or hRrp46p did not
support the growth of GAL::rrp40 or GAL::rrp46 strains, re-
spectively, indicating that the human proteins are unable to
perform all of the essential functions of their yeast homologues.
Detection of hRrp40p, hRrp41p, and hRrp46p in Human
Cells—The cloned cDNAs were expressed as His-tagged and/or
GST-tagged polypeptides using the bacterial and baculovirus
expression systems. In each case this resulted in the synthesis
of proteins with gel mobilities close to those expected for the
predicted molecular weights. The recombinant proteins were
purified by Ni21 or glutathione affinity chromatography and
used to raise rabbit antisera, designated H70 (anti-hRrp40p),
H71 (anti-hRrp41p), and H73 (anti-hRrp46p). All sera recog-
nized the corresponding recombinant His-tagged protein on
Western blots (Fig. 3, A–C, lanes Ag). The reactivity of all
antisera with all three recombinant proteins was analyzed by
Western blotting. Purification of the baculovirus-expressed
hRrp46p might, in principle, have led to the copurification of
the endogenous insect exosome complex; moreover, hRrp46p
and hRrp41p are homologous (see Table III). However, none of
the anti-sera showed detectable cross-reactivity.
To demonstrate that hRrp40p, hRrp41p, and hRrp46p are
expressed in HeLa cells, Western blots containing total HeLa
cell extract were probed with the rabbit antisera (Fig. 3, A–C,
lanes T). Although the sera recognized more than one protein in
the total cell extract, prominent species (indicated by arrow-
heads) were decorated in each case that migrated somewhat
faster than the corresponding recombinant His-tagged proteins
FIG. 1. Schematic representation of the cloning strategy used
to generate the cDNAs encoding hRrp40p, hRrp41p, and
hRrp46p. Sequencing of human EST clones, which were selected based
upon homology with yeast Rrp40p, Rrp41p/Ski6p, and Rrp46p proteins,
resulted in sequence information represented by the cDNA clones.
Additional 59 RACE analyses and PCR analyses on cDNA libraries
complemented the cDNA clones with additional 59 end sequences.
TABLE II
Yeast strains used in this study
YDL401 MATa his3D200 leu2D1 trp1 ura3–52 gal2 galD108 (40)
P147 As YDL401 but GAL10<prot.A-RRP40 (11)
P118 As YDL401 but GAL10<prot.A-RRP41 (40)
YCA21 As YDL401 but GAL10<prot.A-RRP46 (11)
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(Fig. 3, A–C, compare lanes Ag and T). Immunoprecipitation
experiments (see below) confirmed that these correspond to the
hRrp40p, hRrp41p, and hRrp46p.
We conclude that hRrp40p, hRrp41p, and hRrp46p are pres-
ent in HeLa cell lysates and show gel mobilities close to those
expected for their predicted molecular weights.
Subcellular Localization of hRrp40p, hRrp41p, and
hRrp46p—In yeast, 10 out of 11 known components are asso-
ciated with both the cytoplasmic and the nuclear forms of the
exosome, while Rrp6p is detected only in the nucleus (11).
Western blotting experiments showed that hRrp4p and PM/
Scl-75 are components of both nuclear and cytoplasmic com-
plexes in human cells, while PM/Scl-100 (the homologue of
Rrp6p) appears to be solely nuclear (11).
To determine the subcellular distribution of hRrp40p,
hRrp41p, and hRrp46p, HeLa cells were separated into three
fractions: cytoplasmic extract (C), nuclear extract (N), and the
nuclear material retained after salt extraction (R). The mate-
rial of an equal number of cells (5 3 105 cells) from each
fraction was used for Western blotting. As controls for the
fractionation, we analyzed the largely cytoplasmic histidyl-
tRNA synthetase (Jo-1, Fig. 3F), the nuclear DNA topoisomer-
ase I (DNA Topo I, Fig. 3G), and the nuclear matrix-associated
protein lamin B (Fig. 3H). The positions of migration are indi-
cated by arrowheads. These results confirmed that the cells
were fractionated as expected.
Western blots were probed with the rabbit sera H70 (Fig.
3A), H71 (Fig. 3B), and H73 (Fig. 3C). hRrp40p, hRrp41p, and
hRrp46p were each detected in both the nuclear (N) and cyto-
plasmic (C) fraction, with lower yields in the cytoplasm (C).
Weaker signals were seen in residual nuclear material after
salt extraction (R). A similar distribution was found for hRrp4p
(Fig. 3D). In contrast, PM/Scl-100 was recovered almost en-
tirely in the nuclear fraction (Fig. 3E).
To confirm the subcellular localization of hRrp40p, hRrp41p,
and hRrp46p, polypeptides carrying N-terminal and C-termi-
nal VSV tags were expressed in HEp-2 cells. Indirect immuno-
fluorescence of cells transfected with these constructs showed
that all of these VSV-tagged proteins were strongly enriched in
the nucleoli (Fig. 4). In addition, a weaker diffuse staining was
widely distributed in the nucleoplasm and cytoplasm. Indirect
immunofluorescence using the rabbit antisera H70 and H73
also resulted in prominent staining of the nucleoli of HEp-2
cells. Rabbit antiserum H71 did not give signals in indirect
immunofluorescence (data not shown).
We conclude that hRrp40p, hRrp41p, and hRrp46p are pres-
ent in both the cytoplasm and nucleus, with the highest con-
centration in the nucleolus.
hRrp40p, hRrp41p, and hRrp46p Are Part of the PM/Scl
Complex—The previously identified components of the human
exosome (hRrp4p, PM/Scl-75, and PM/Scl-100) cosedimented in
a large complex on glycerol gradient centrifugation of HeLa cell
lysates (11). To determine whether hRrp40p, hRrp41p, and
hRrp46p are associated with complexes of similar size, HeLa
cell extracts were fractionated by size exclusion
chromatography.
Cytoplasmic and nuclear extracts were prepared from 75 3
106 cells and separately fractionated by chromatography on a
Superdex 200 column. For each extract, 30 fractions were col-
lected and analyzed by Western blotting with rabbit antisera
H70, H71, H73, anti-hRrp4p, and anti-PM/Scl-100 (Fig. 5).
These analyses revealed that hRrp40p, hRrp41p, and hRrp46p
are associated with relatively large complexes in the cytoplas-
mic (Fig. 5A) and nuclear (Fig. 5B) extracts. All three proteins
cofractionated with PM/Scl-100 and hRrp4p in both the cyto-
plasmic and nuclear extracts.
To estimate the size of the complexes, gel filtration standards
were fractionated using the same conditions. In the cytoplas-
mic extract, the exosome components peaked in fractions three
and four corresponding to a molecular mass of ;700 kDa. In
the nuclear extract, all exosome proteins analyzed except PM/
Scl-100 showed a broader distribution over fractions 3–11, cor-
responding to estimated molecular masses of ;250–700 kDa.
FIG. 2. Complementation of growth defects in yeast strain de-
pleted of Rrp40p, Rrp41p/Ski6p, or Rrp46p by the human homo-
logues. Figure shows plate assay for growth of GAL::Rrp40,
GAL::Rrp41, and GAL::Rrp46 transformed with phRrp40p, phRrp41p,
and phRrp46p, respectively, on repressive YPD medium. WT, wild-type.
TABLE III
Mma Ceb Spc Scd hRrp40p hRrp41p hRrp46p
hRrp40p 88/91e 34/56 31/50 30/46 100/100 12/26 18/28
hRrp41p 96/97 44/62 42/57 35/54 12/26 100/100 28/43
hRrp46p 89/93 31/46 29/46 26/42 18/28 28/43 100/100
a Polypeptide encoded by contig assembled with mouse (M. musculus) ESTs.
b Caenorhabditis elegans protein entries in data base (ceRrp40p:CAB01875, ceRrp40p: Q17533, ceRrp46p: CAA90109).
c Schizosaccharomyces pombe protein entries in data base (spRrp40p: CAB16582, spRrp41p: BAA13803, spRrp46p: CAA17913).
d Saccharomyces cerevisiae protein entries in data base (scRrp40p: NPo01499, scRrp41p: NPo011711, scRrp46p: NPo011609).
e Values are percentages of identical and similar amino acid residues, respectively.
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The peak of PM/Scl-100 was limited to fractions 3 and 4, sug-
gesting association with only the higher molecular weight com-
plexes. Similar results were obtained following fractionation of
nuclear extracts by glycerol gradient centrifugation, which
showed cosedimentation of hRrp40p and hRrp41p with hRrp4p
and the PM/Scl autoantigens (data not shown).
Coimmunoprecipitation experiments were performed to con-
firm the physical association of hRrp40p, hRrp41p, and
hRrp46p with the known human exosome components. Five
anti-PM/Scl-positive patient sera were used to immunoprecipi-
tate the exosome complex from a HeLa cell nuclear extract;
three anti-PM/Scl-negative sera served as controls (Fig. 6A).
The immunoprecipitates were analyzed by Western blotting
using the rabbit antisera H70, H71, and H73. hRrp40, hRrp41,
and hRrp46 were each immunoprecipitated by the anti-PM/Scl-
positive sera, but not by the control sera. Although the rabbit
antisera showed reactivity with several proteins present in the
total nuclear extract (Fig. 6A, lanes i), each rabbit antiserum
consistently stained only one protein in the immunoprecipi-
tates. In each case the gel mobility corresponded with the
predicted molecular weight, confirming that these represent
the cognate proteins.
In the converse experiments, sera H70, H71, and H73 were
used for immunoprecipitation and the coprecipitation of PM/Scl
autoantigens was detected with two anti-PM/Scl patient sera,
Lun7 and Lun36. Sera H70 and H73 each coimmunoprecipi-
tated PM/Scl-100 from a nuclear HeLa cell extract (Fig. 6B,
right panel). In addition, both patient sera stained several
smaller proteins that were immunoprecipitated by H70 and
H73 from the nuclear extract, which may represent other com-
ponents of the PM/Scl particle. Neither pre-immune sera (PI
lanes) precipitated the PM/Scl-100 autoantigen or any of the
smaller proteins. PM/Scl-100 was also coimmunoprecipitated
at low levels from a cytoplasmic extract by sera H70 and H73
(Fig. 6B, left panels). Serum H71 failed to precipitate PM/Scl-
100 (Fig. 6B) and also failed to decorate the nucleoli of HEp-2
cells in immunofluorescence microscopy (data not shown). This
may be due either to inaccessibility of hRrp41p in the complex
or to the inability of the antibodies to recognize native
hRrp41p.
We conclude that hRrp40p, hRrp41p, and hRrp46p are pres-
ent in a complex containing the known human exosome com-
ponents, PM/Scl-100 and hRrp4p.
Exoribonuclease Activity of the Complexes Containing
hRrp40p, hRrp41p, and hRrp46p—The human exosome com-
plex was immunoprecipitated from a HeLa cell extract using
rabbit antisera H70, H71, and H73 or anti-PM/Scl-positive
patient serum R212. The pre-immune rabbit sera and a pool of
FIG. 3. Western blot analyses of fractionated HeLa cells to determine the subcellular distribution of exosome components. HeLa
cells were lysed by hypotonic Dounce homogenizer, nuclei were extracted with 0.3 M NaCl, and the retained nuclear material was recovered after
sonification of the salt-extracted nuclei. Western blots containing total (T), cytoplasmic (C), nuclear (N), and retained nuclear (R) HeLa cell
fractions, each obtained from an equal number of cells, were probed with rabbit antisera reactive with hRrp40p (panel A), hRrp41p (panel B),
hRrp46p (panel C), hRrp4p (panel D), or PM/Scl-100 (panel E). Western blots were also decorated with autoimmune patient sera reactive with
histidyl-tRNA synthetase (Jo-1, panel F), with DNA topoisomerase I (panel G), or with monoclonal antibodies reactive with lamin B (panel H). The
relevant proteins are indicated by arrowheads. Western blots in panels A–C also contain the corresponding recombinant His-tagged proteins (Ag
lanes).
FIG. 4. Nucleolar accumulation of the VSV-tagged hRrp40p,
hRrp41p, and hRrp46p in HEp-2 cells. HEp-2 cells were transfected
with VSV-tagged constructs by electroporation and cultured for 24 h at
37 °C. The localization of C-terminally VSV-tagged hRrp40p (A),
hRrp41p (B), and hRrp46p (C) was determined by indirect immunoflu-
orescence using a monoclonal anti-VSV tag antibody (left panels). The
corresponding phase-contrast images are shown on the right.
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10 normal human sera served as negative controls. Associated
exoribonuclease activity was assayed in vitro with an inter-
nally labeled 37-nucleotide single-stranded RNA substrate.
The immunoprecipitates obtained with rabbit antisera H70
and H73 and patient serum R212 exhibited ribonuclease activ-
ity, with progressive disappearance of the RNA substrate and
the accumulation of the labeled end-product (Fig. 7, left panel,
lanes 2–4 and 8–13). Analysis of the reaction products by thin
layer chromatography revealed that the accumulating end
products are nucleoside monophosphates consistent with exo-
nucleolytic degradation of the substrate (data not shown).
Omission of phosphate from the buffer used in this assay,
which has been shown to affect the activity of yeast Rrp41p/
Ski6p (12), did not significantly inhibit the reaction (data not
shown). Immunoprecipitates obtained with rabbit antiserum
H71 (Fig. 7, left panel, lanes 5–7) and the control sera (Fig. 7,
right panel) did not show nucleolytic activities. The similar
patterns of reaction products seen with H70 and H73 indicate
that the complexes immunoprecipitated by each serum are
related.
When the substrate was 39-labeled with 32P, incubation with
the immunoprecipitates obtained with sera H70, H73, or R212
resulted in the disappearance of the RNA substrate without
detectable intermediate products. We conclude that the immu-
noprecipitated complexes exhibit 39 3 59 exonuclease activity.
Removal of the 39 phosphate group, inherently introduced by
the [32P]pCp labeling procedure, resulted in a slightly en-
hanced reaction (data not shown) indicating a preference for a
39-hydroxyl residue, as seen for the yeast exosome (12).
These results show that hRrp40 and hRrp46 are associated
with a complex displaying 39 3 59 exoribonuclease activity in
vitro. We conclude that these proteins are indeed novel human
exosome components.
DISCUSSION
We have characterized three novel human polypeptides,
hRrp40p, hRrp41p, and hRrp46p, encoded by cDNAs that were
isolated on the basis of homology to the yeast exosome compo-
nents Rrp40p, Rrp41p/Ski6p, and Rrp46p, respectively (11).
Western blotting experiments using rabbit antisera raised
against each of the recombinant proteins showed that HeLa
cells express proteins of the predicted molecular weights. Con-
sistent with data previously obtained for human exosome com-
ponents, all three proteins are present in both the cytoplasm
and nucleus, with nucleolar enrichment. The novel proteins
were shown to be part of a large complex cofractionating with
hRrp4p and PM/Scl-100. The physical association with the
PM/Scl autoantigens was confirmed by coimmunoprecipitation.
Functional assays demonstrated that the complexes containing
hRrp40p and hRrp46p display 393 59 exoribonuclease activity
in vitro. Moreover, expression of hRrp41p in yeast is able to
support the growth of cells depleted of yeast Rrp41p/Ski6p. We
conclude that hRrp40p, hRrp41p, and hRrp46p are novel com-
ponents of the human exosome complex.
Subcellular Localization of hRrp40p, hRrp41p and
hRrp46p—Consistent with previous data using anti-PM/Scl
positive patient sera, hRrp40p, hRrp41p, and hRrp46p were
shown by indirect immunofluorescence to be enriched in the
nucleolus. However, subcellular fractionation showed that
hRrp40p, hRrp41p, and hRrp46p are present in both nuclear
and cytoplasmic fractions, as is hRrp4p (11). Salt extraction
released most of the nuclear hRrp40p, hRrp41p, and hRrp46p,
FIG. 5. hRrp40p, hRrp41p, and
hRrp46p are associated with high
molecular weight complexes in HeLa
cells. A, cytoplasmic extract. B, salt-ex-
tractable nuclear extract. Lysates (from
an equal number of cells) were fraction-
ated by size exclusion chromatography
and fractions 2–27 were analyzed by
Western blotting using rabbit antisera
specific for hRrp40p (I), hRrp41p (II),
hRrp46p (III), hRrp4p (IV), and PM/Scl-
100 (V). In the left lanes (i), total cytoplas-
mic or nuclear extract was loaded. Note
that serum H73 is also reactive with a
cytoplasmic polypeptide that migrates
slightly faster than hRrp46p (see also Fig.
3C), but fractionated only in the lower
molecular weight fractions (panel A, III,
indicated by *).
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but a substantial amount of each protein was retained. The
release of DNA topoisomerase I indicated that the high salt
extraction was efficient. We speculate that the extracted and
retained fractions represent nucleoplasmic and nucleolar pools
of the exosome, respectively. Diffusely distributed nucleoplas-
mic and cytoplasmic populations are presumably less visible in
immunofluorescence than is the nucleolar population.
The distribution of the human exosome components is simi-
lar to that previously seen for yeast Rrp4p and Rrp43p (11, 40).
The yeast exosome is implicated in RNA processing reactions in
the nucleolus (pre-rRNA processing and spacer degradation),
nucleoplasm (pre-small nucleolar RNA and pre-small nuclear
RNA processing and pre-mRNA degradation) and cytoplasm
(mRNA degradation) (12–23), and the distribution observed for
exosome components presumably reflects these functions. The
similarities in the distribution patterns, and the complemen-
tation of yeast mutants by the human proteins, make it likely
that the human exosome will carry out many or all of the same
functions.
The yeast exosome is implicated in the degradation of un-
spliced pre-mRNAs (18, 22) and might therefore influence the
outcome of alternative splicing events. The identification of
cDNAs that apparently result from alternative splicing of
hRRP40 and hRRP46 therefore raises interesting possibilities
for autogenous regulation.
Characterization of the Complex Containing hRrp40p,
hRrp41p, and hRrp46p—Immunoprecipitation with anti-PM/
Scl-positive patient sera, using metabolically labeled human
cell extracts, indicated that the PM/Scl complex consists of at
least 11 proteins (25, 26). The estimated molecular masses of
the proteins found in these studies were 110, 90, 80, 39, 37, 33,
30, 27, 26, 22, and 20 kDa. Comparison of these molecular
masses with those of the proteins characterized in the present
study suggested that hRrp40, hRrp41 and hRrp46 correspond
to the 30-, 27-, and 26-kDa proteins, respectively.
Size exclusion chromatography of the exosome complex in a
HeLa cell extract, indicated that the cytoplasmic complex has a
molecular mass of ;700 kDa. The nuclear complex gave a
broad distribution between 250 and 700 kDa. These complex
sizes were estimated based upon the separation of gel filtration
standards. However, this fractionation may not be dependent
solely on the mass of the complex, but may also reflect its
FIG. 6. hRrp40p, hRrp41p, and hRrp46p are physically associated with the human exosome. A, coimmunoprecipitation experiments
were performed using five anti-PM/Scl-positive patient sera (lanes 1–5) and three anti-PM/Scl-negative patient sera (lanes 6–8). Immunoprecipi-
tated material was analyzed by Western blotting using the rabbit antisera raised against hRrp40p (H70), hRrp41p (H71), or hRrp46p (H73) to
detect coimmunoprecipitation of these proteins. In lanes i, total nuclear extract (30%) used for immunoprecipitation was loaded. B, Western blot
analyses of the converse experiment in which the preimmune (PI, lanes 2, 4, 6, 10, 12, and 14) and immune (I, lanes 3, 5, 7, 11, 13, and 15) rabbit
antisera were used for the immunoprecipitations and two anti-PM/Scl-positive patient sera, Lun7 (lower panels) and Lun36 (upper panels), were
used for detection. Cytoplasmic (lanes 1–8) and salt-extractable nuclear (lanes 9–16) HeLa cell extracts were used for immunoprecipitations. Total
cytoplasmic and nuclear extract was loaded in lanes i (lanes 1 and 8 (cytoplasmic) and lanes 9 and 16 (nuclear)). Arrowheads indicate the relevant
proteins.
FIG. 7. hRrp40p- and hRrp46p-containing complexes display ribonuclease activity in vitro. Immunoprecipitated hRrp40p, hRrp41p,
hRrp46p, and PM/Scl antigens containing complexes from HeLa cells were assayed for exoribonuclease activity in vitro. A uniformly 32P-labeled
RNA substrate was incubated with the immunoprecipitates of anti-hRrp40p (H70), anti-hRrp41p (H71), and anti-hRrp46p (H73) rabbit sera or an
anti-PM/Scl-positive patient serum (R212). Samples taken after 10, 20, and 30 min of incubation at 37 °C were analyzed by 10% denaturing
polyacrylamide gel electrophoresis followed by autoradiography (left panel). Control experiments (right panel) were performed using the immu-
noprecipitates of the corresponding preimmune rabbit antisera (PI-H70, PI-H71, and PI-H73) or a pool of ten normal human sera (NHS). In the
left lanes (i), input RNA substrate was loaded.
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structure relative to the protein size markers. It is also unclear
whether the size distribution of the nuclear exosome reflects
the existence of multiple, heterogeneous complexes or whether
it is due to instability of the complex. The size of the human
exosome complex estimated by size exclusion chromatography
was larger than previously estimated from glycerol gradient
centrifugation (12), presumably reflecting differences in the
physical basis of the separation techniques.
The complexes immunoprecipitated with anti-hRrp40p
(H70) or anti-hRrp46p (H73) showed very similar in vitro ac-
tivities. In each case, both processive and distributive activities
are suggested by the data. A distributive exonuclease activity
removes one (or a few) nucleotide(s) before dissociating from
the substrate. In consequence, its activity is “distributed” over
the entire substrate population, which is therefore progres-
sively shortened in approximate synchrony. Such an activity
would be consistent with the shortening of the RNA population
near the top of the gel in the H70 and, particularly, H73 lanes
in Fig. 7 (lanes 2–4 and 8–10, respectively). In contrast, bind-
ing of a processive exonuclease to the a molecule of substrate
results in its rapid degradation to a short residual fragment, at
which point the RNA is too short for the enzyme to bind. In
consequence, a fraction of the substrate is rapidly shortened,
while most of the substrate in untouched. Such an activity may
be seen in the early time points of using the H70 and H73
immunoprecipitates shown in Fig. 7.
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